首页> 外文期刊>Journal of pediatric endocrinology & metabolism: JPEM >Final diagnosis in children with subclinical hypothyroidism and mutation analysis of the thyroid peroxidase gene (TPO).
【24h】

Final diagnosis in children with subclinical hypothyroidism and mutation analysis of the thyroid peroxidase gene (TPO).

机译:亚临床甲状腺功能减退症儿童的最终诊断和甲状腺过氧化物酶基因(TPO)的突变分析。

获取原文
获取原文并翻译 | 示例
           

摘要

AIM: To determine the final diagnosis of patients with subclinical hypothyroidism (SCH), and to perform mutation screening of the thyroid peroxidase gene (TPO). METHODS: Infants with SCH without an identified etiology were included in the study. Patients with thyroid dysgenesis were excluded. Children > or = 2 years of age, and still on L-thyroxine (LT4) treatment underwent a diagnostic algorithm. After LT4 was discontinued for 4 weeks, thyroid function tests (TFT) were obtained. A perchlorate discharge test (PDT) was performed in patients with normal thyroid ultrasound but abnormal TFT. Sequence analysis of TPO was studied in all children who underwent a PDT. RESULTS: Forty-eight patients (23 males and 25 females) completed the trial. Among these children, 19 (39.5%) had transient SCH, and 29 (60.5%) had permanent SCH. Among patients with permanent SCH, 19 had thyroid hypoplasia, six had partial iodide organification defect with positive PDT, and four had other dyshormonogenesis with negative PDT. Mean LT4 dose before the medication ceased was 1.2 +/- 0.5 microg/kg/day in transient cases, and 1.7 +/- 0.4 in those with permanent SCH (p < 0.05). No TPO mutation was detected. However, in five patients, seven different previously known TPO polymorphisms were detected: c.102C > G, L4L; > A, A576A; c.2088C > T, D666D; c.2263A > C, T725P; c.2630 T >C, V847A. CONCLUSIONS: LT4 treatment should be stopped after the age of 2 years in infants with SCH without a definite pathology of the thyroid gland to exclude cases with transient hypothyroidism. Additionally, we should consider particularly thyroid gland hypoplasia, and also partial defects in iodide organification in infants with SCH.
机译:目的:确定亚临床甲状腺功能减退症(SCH)患者的最终诊断,并对甲状腺过氧化物酶基因(TPO)进行突变筛查。方法:本研究纳入了未发现病因的SCH婴儿。排除甲状腺功能不全的患者。大于或等于2岁的儿童仍接受L-甲状腺素(LT4)治疗,接受了诊断算法。 LT4停药4周后,进行甲状腺功能测试(TFT)。甲状腺超声正常但TFT异常的患者进行了高氯酸盐放电测试(PDT)。在所有接受PDT的儿童中研究了TPO的序列分析。结果:48例患者(男23例,女25例)完成了试验。在这些儿童中,有19名(39.5%)患有短暂性SCH,而29名(60.5%)具有永久性SCH。在永久性SCH患者中,有19例甲状腺发育不全,有6例PDT阳性的部分碘化物组织缺陷,有4例PDT阴性的其他激素异常。在短暂性用药情况下,停药前的LT4平均剂量为1.2 +/- 0.5 microg / kg /天,在永久性SCH患者中为1.7 +/- 0.4(p <0.05)。未检测到TPO突变。但是,在五名患者中,检测到七个不同的先前已知的TPO多态性:c.102C> G,L4L; > A,A576A; c.2088C> T,D666D; c.2263A> C,T725P; c.2630 T> C,V847A。结论:对于没有明确甲状腺病理的SCH患儿,在2岁后应停止LT4治疗,以排除短暂性甲状腺功能减退的病例。此外,我们应该特别考虑SCH婴儿的甲状腺发育不全,以及碘化物组织的部分缺陷。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号